Galapagos NV ADR

Yahoo Finance • 8 days ago

Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets

Galapagos NV (NASDAQ:GLPG) is one of the 7 Fastest Growing European Stocks to Invest In. On March 31, 2026, Galapagos NV (NASDAQ:GLPG) announced a binding agreement with Gilead Sciences (NASDAQ:GILD) related to Gilead’s planned acquisitio... Full story

Yahoo Finance • 13 days ago

Galapagos NV, Gilead Sciences strike deal tied to Ouro Medicines acquisition

Galapagos NV (GLPG [https://seekingalpha.com/symbol/GLPG]) Tuesday said that it has entered into a binding agreement [https://seekingalpha.com/pr/20456224-galapagos-and-gilead-enter-into-binding-agreement-to-collaborate-on-advancing-first-... Full story

Yahoo Finance • 13 days ago

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions... Full story

Yahoo Finance • 13 days ago

Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen

De nieuwe samenwerkingsstructuur levert aanzienlijk verbeterde financiële voorwaarden en flexibiliteit voor Galapagos op Na deze transactie blijft de Vennootschap over het grootste deel van haar liquide middelen beschikken voor bijkomende... Full story

Yahoo Finance • 20 days ago

Gilead to buy Ouro Medicines for up to $2.2 billion

Investing.com -- Gilead Sciences Inc. announced Monday it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. Th... Full story

Yahoo Finance • 26 days ago

Galapagos Receives Transparency Notification from Bank of America

Galapagos NV Mechelen, Belgium; March 117, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America. Pursuant to Belgian transparency legislation1, Galapago... Full story

Yahoo Finance • last month

CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight

The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD, SLE, multiple sclerosis, and other relate... Full story

Yahoo Finance • last month

Galapagos Receives Transparency Notifications from Bank of America

Galapagos NV Mechelen, Belgium; March 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos... Full story

Yahoo Finance • last month

Galapagos Receives Transparency Notifications from Bank of America  

Mechelen, Belgium; March 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received trans... Full story

Yahoo Finance • last month

Galapagos ontvangt transparantieverklaringen van Bank of America  

Mechelen, België; 10 maart 2026, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft transparantieverklaringen ontvangen van Bank of America. Overeenkomstig de Belgische transparantiewetgeving1 ontving Ga... Full story

Yahoo Finance • 2 months ago

Galapagos NV (GLPG) Full Year 2025 Earnings Call Highlights: Strategic Shifts and Financial ...

This article first appeared on GuruFocus. Cash Position: Approximately EUR3 billion at year end 2025. Operating Profit: EUR295.1 million in 2025, compared to an operating loss of EUR188.3 million in 2024. Deferred Income Revenue: EUR1,069... Full story

Yahoo Finance • 2 months ago

Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Galapagos NV Strategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute on a business developme... Full story

Yahoo Finance • 2 months ago

Galapagos ontvangt transparantieverklaring van Bank of America

Mechelen, België; 16 februari 2026, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft een transparantieverklaring ontvangen van Bank of America. Overeenkomstig de Belgische transparantiewetgeving1 ontvi... Full story

Yahoo Finance • 4 months ago

Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus

GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the systemic lupus erythematos... Full story

Yahoo Finance • 4 months ago

Galapagos maakt topline resultaten bekend van twee fase 3-enabling studies met selectieve TYK2-remmer GLPG3667 bij dermatomyositis en systemische lupus erythematodes

GLPG3667 bereikte het primaire eindpunt in de dermatomyositis-studie en toonde een statistisch significant klinisch voordeel en betekenisvolle verbeteringen aan op secundaire eindpunten van ziekteactiviteit in vergelijking met placebo In... Full story

Yahoo Finance • 4 months ago

Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time Me... Full story

Yahoo Finance • 4 months ago

Galapagos presenteerde nieuwe ATALANTA-1 celtherapiedata in MCL op ASH 2025

Hoge percentages complete respons en minimale residuele ziekte (MRD)-negativiteit, met duurzame responsen, bij hoog-risico mantelcellymfoom (MCL) met GLPG5101, een verse, early-memory verrijkte CAR T-celtherapie met een vein-to-vein-tijd v... Full story

Yahoo Finance • 5 months ago

Galapagos ontvangt transparantieverklaringen van Bank of America

Mechelen, België; 26 november 2025, 07:30 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft transparantieverklaringen ontvangen van Bank of America. Overeenkomstig de Belgische transparantiewetgeving1 ontving... Full story

Yahoo Finance • 5 months ago

Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development

Galapagos NV New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced se... Full story

Yahoo Finance • 5 months ago

Galapagos kondigt wijzigingen aan in de Raad van Bestuur om de strategische focus op business development te versnellen

Nieuwe bestuurders brengen sterke financiële leiderschapservaring, expertise in kapitaalallocatie en business development naar de Raad van Bestuur Mechelen, België; 30 oktober 2025, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondig... Full story